Exelixis Net Cash Flow 2010-2025 | EXEL

Exelixis net cash flow for the twelve months ending June 30, 2025 was $-0.137B, a 66.91% decline year-over-year.

  • Exelixis annual net cash flow for 2024 was $-0.046B, a 80.97% decline from 2023.
  • Exelixis annual net cash flow for 2023 was $-0.24B, a 48.67% increase from 2022.
  • Exelixis annual net cash flow for 2022 was $-0.161B, a 146.98% decline from 2021.

Exelixis Net Cash Flow 2010-2025 | EXEL

  • Exelixis annual net cash flow for 2024 was $-0.046B, a 80.97% decline from 2023.
  • Exelixis annual net cash flow for 2023 was $-0.24B, a 48.67% increase from 2022.
  • Exelixis annual net cash flow for 2022 was $-0.161B, a 146.98% decline from 2021.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$231.3B
Amgen (AMGN)$162.4B
Gilead Sciences (GILD)$142.4B
Vertex Pharmaceuticals (VRTX)$121.3B
Bristol Myers Squibb (BMY)$92.4B
CSL (CSLLY)$84B
GSK (GSK)$76.9B
Regeneron Pharmaceuticals (REGN)$61.7B
Alnylam Pharmaceuticals (ALNY)$55B
Argenex SE (ARGX)$42.2B
BioNTech SE (BNTX)$26.5B
Royalty Pharma (RPRX)$21.3B
Insmed (INSM)$21.1B
Biogen (BIIB)$19.4B
Incyte (INCY)$15.2B
Illumina (ILMN)$15.1B
Genmab (GNMSF)$14.7B
Genmab (GMAB)$14.1B
BioMarin Pharmaceutical (BMRN)$11.6B
Ascendis Pharma (ASND)$11.3B
QIAGEN (QGEN)$11.2B
Moderna (MRNA)$10.8B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Verona Pharma American Depositary Share (VRNA)$9B
Exact Sciences (EXAS)$8.8B
Bio-Techne Corp (TECH)$8.6B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$7.8B
Halozyme Therapeutics (HALO)$7.4B
Legend Biotech (LEGN)$7.1B